

How microplastics in blood may trigger acute myocardial infarction.

Written by The Life Science Feed Editorial Team · Published 23 July 2026 · Edited by Mara Voss

Cardiovascular disease remains the leading cause of mortality globally, with myocardial infarction representing a significant clinical burden. While traditional risk factors like hypertension, dyslipidemia, and diabetes are well-established, emerging environmental exposures warrant closer examination.

New research indicates that the presence of micro and nanoplastic particles in the bloodstream may contribute to the pathogenesis of acute coronary syndromes, adding a novel dimension to our understanding of cardiovascular risk.

KEY TAKEAWAYS

- **The Pivot:** Environmental microplastic exposure is now being directly linked to acute cardiovascular events, moving beyond theoretical concerns.
- **The Data:** Patients with acute myocardial infarction exhibit significantly elevated levels of plastic particles in their blood compared to healthy controls.
- **The Action:** Clinicians should be aware of emerging environmental risk factors, though direct interventions for plastic exposure remain undefined.

The human body is increasingly exposed to micro and nanoplastics through ingestion, inhalation, and dermal contact. These ubiquitous particles, fragments of larger plastic items, are now detectable in various biological matrices, including blood. The question of whether these microscopic invaders contribute to disease pathology, particularly in the cardiovascular system, has moved from speculative to empirical.

A recent observational study investigated the presence and concentration of micro and nanoplastics in the blood of patients presenting with acute myocardial infarction (AMI) compared to healthy controls. The study enrolled 100 patients diagnosed with AMI and 100 age- and sex-matched healthy individuals. Investigators collected peripheral blood samples from all participants upon admission, before any invasive procedures or major medical interventions, to ensure baseline assessment of plastic particle load.

Detecting the invisible invaders

Researchers employed advanced analytical techniques, including pyrolysis-gas chromatography/mass spectrometry (Py-GC/MS) and Raman microspectroscopy, to identify and quantify specific plastic polymers in the blood samples. These methods allowed for the detection of particles ranging from several micrometers down to nanometer scale. The focus was on common plastic types such as polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC), and polyethylene terephthalate (PET), which are prevalent in everyday consumer products and packaging.

The primary finding revealed a significantly higher concentration of micro and nanoplastic particles in the blood of patients with AMI compared to the healthy control group. The mean total plastic concentration in AMI patients was $12.5 \pm 3.2 \mu\text{g/mL}$, while in healthy controls, it was $4.1 \pm 1.8 \mu\text{g/mL}$ ($P < .001$). This difference was consistent across various plastic types, with PE and PET being the most commonly detected polymers in both groups, but at markedly elevated levels in the AMI cohort.

Specific plastic types and their prevalence

Polyethylene (PE) was detected in 85% of AMI patients and 45% of healthy controls. Polyethylene terephthalate (PET) appeared in 78% of AMI patients and 38% of healthy controls. Polypropylene (PP) was less frequent but still more common in the AMI group, found in 55% of patients versus 20% of controls. These data suggest a pervasive presence of these particles, but a distinct accumulation in individuals experiencing acute cardiac events.

The study also explored potential mechanisms by which these particles might exert cardiovascular harm. Microplastics, once in the bloodstream, can induce inflammatory responses, oxidative stress, and endothelial dysfunction. These are all well-known contributors to atherosclerosis and acute thrombotic events. The small size of nanoplastics, in particular, allows them to cross biological barriers, potentially accumulating in tissues like the myocardium or arterial walls, where they could directly interfere with cellular function.

The inflammatory cascade

Investigators observed elevated levels of inflammatory markers, including C-reactive protein (CRP) and interleukin-6 (IL-6), in AMI patients with higher plastic loads. While this correlation does not establish causation, it supports the hypothesis that plastic particles may act as chronic irritants, exacerbating systemic inflammation. This persistent inflammatory state could destabilize atherosclerotic plaques, increasing the risk of rupture and subsequent myocardial infarction.

The study was observational, which means it cannot definitively prove that microplastics cause heart attacks. It establishes a strong association, but confounding factors, such as lifestyle, diet, and other environmental exposures, were not fully controlled for in this initial analysis. A larger, prospective cohort study would be necessary to delineate a causal pathway and quantify the independent risk conferred by plastic particle exposure.

Still, the implications are considerable. If microplastic accumulation is indeed a modifiable risk factor, it opens new avenues for public health interventions. Reducing environmental plastic pollution and minimizing human exposure could become a component of cardiovascular disease prevention strategies. For now, the focus remains on understanding the precise biological interactions and long-term effects of these ubiquitous contaminants. The Oxford Handbook of Cardiology provides a comprehensive overview of established and emerging risk factors in cardiac health.

The trial was not powered to detect differences in specific plastic polymer types and their individual contributions to AMI risk, and that gap matters. Future research must differentiate the impact of various plastic compositions and sizes, as their biological activity may vary significantly. The current study provides a critical first step in linking environmental contaminants to acute cardiovascular events, but the full picture of causality and intervention remains to be painted.

CLINICAL IMPLICATIONS

The presence of micro and nanoplastics in the blood of patients with acute myocardial infarction adds an unsettling dimension to cardiovascular risk assessment. Clinicians are already managing a complex array of traditional risk factors, and now face the prospect of environmental contaminants playing a direct role in disease pathogenesis.

While we lack specific interventions to reduce a patient's plastic load, this research underscores the broader public health imperative to address plastic pollution. It suggests that environmental health is inextricably linked to individual patient outcomes, a concept that will increasingly shape preventive medicine.

For now, the data provides a compelling association, not a definitive mechanism. But it forces us to consider how ubiquitous environmental factors, previously dismissed as inert, might contribute to the inflammatory and thrombotic processes driving acute coronary syndromes. This is a call for vigilance, not immediate changes in practice, but a recognition that the clinical picture is becoming more complex.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. The Conversation. Do patients who suffer heart attack have more micro and nanoplastic in their blood? New study assessed. Accessed Jul 2026.
<https://theconversation.com/do-patients-who-suffer-heart-attack-have-more-micro-and-nanoplastic-in-their-blood-new-study-assessed-287711>

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** [linkedin.com/company/thelifesciencefeed](https://www.linkedin.com/company/thelifesciencefeed)

thelifesciencefeed.com